These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 4020620)

  • 21. Diphenhydramine disposition in chronic liver disease.
    Meredith CG; Christian CD; Johnson RF; Madhavan SV; Schenker S
    Clin Pharmacol Ther; 1984 Apr; 35(4):474-9. PubMed ID: 6705445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cimetidine kinetics and dynamics in patients with severe liver disease.
    Villeneuve JP; Fortunet-Fouin H; Arsène D
    Hepatology; 1983; 3(6):923-7. PubMed ID: 6629322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Altered disposition and availability of cimetidine in liver cirrhotic patients.
    Gugler R; Müller-Liebenau B; Somogyi A
    Br J Clin Pharmacol; 1982 Sep; 14(3):421-30. PubMed ID: 7126415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetics of sulphafurazole in undernutrition.
    Shastri RA
    Br J Clin Pharmacol; 1980 Nov; 10(5):499-502. PubMed ID: 7437262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulin uptake by the human alcoholic cirrhotic liver.
    Nygren A; Adner N; Sundblad L; Wiechel KL
    Metabolism; 1985 Jan; 34(1):48-52. PubMed ID: 3880856
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese.
    Garrett ER; Süverkrup RS; Eberst K; Yost RL; O'Leary JP
    Biopharm Drug Dispos; 1981; 2(4):329-65. PubMed ID: 7317572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum protein binding of sulfisoxazole and diazepam in patients with chronic obstructive pulmonary disease.
    Guerrero J; García-Morillas M; Gil-Extremera B; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1987 May; 25(5):255-8. PubMed ID: 3596851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship between protein binding of bilirubin, salicylic acid, and sulfisoxazole in serum of unmedicated and phenobarbital-treated rats.
    Yacobi A; Oie S; Levy G
    J Pharm Sci; 1977 Jul; 66(7):1025-7. PubMed ID: 886438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease.
    DeVane CL; Laizure SC; Stewart JT; Kolts BE; Ryerson EG; Miller RL; Lai AA
    J Clin Psychopharmacol; 1990 Oct; 10(5):328-32. PubMed ID: 2124217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Rate of elimination of the sulfonamide sulfisoxazole in children in the 1st year of life: diurnal fluctuations].
    Krauer B
    Int Z Klin Pharmakol Ther Toxikol; 1969 Jul; 2(3):217-20. PubMed ID: 5357864
    [No Abstract]   [Full Text] [Related]  

  • 33. Pharmacokinetic disposition of isoxicam in hepatic cirrhosis.
    Esquivel M; Ogilvie RI; East DS; Shaw DH; Heathcote J
    Clin Invest Med; 1987 Sep; 10(5):363-7. PubMed ID: 3677504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity.
    Barre J; Mallat A; Rosenbaum J; Deforges L; Houin G; Dhumeaux D; Tillement JP
    Br J Clin Pharmacol; 1987 Jun; 23(6):753-7. PubMed ID: 3606934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced bioavailability of pethidine and pentazocine in patients with cirrhosis of the liver.
    Pond SM; Tong T; Benowitz NL; Jacob P
    Aust N Z J Med; 1980 Oct; 10(5):515-9. PubMed ID: 6937164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. OBSERVATIONS ON PATIENTS WITH LAENNEC'S CIRRHOSIS RECEIVING ALCOHOL WHILE ON CONTROLLED DIETS.
    ERENOGLU E; EDREIRA JG; PATEK AJ
    Ann Intern Med; 1964 May; 60():814-23. PubMed ID: 14156608
    [No Abstract]   [Full Text] [Related]  

  • 37. Removal systems of immunoglobulin A and immunoglobulin A containing complexes in IgA nephropathy and cirrhosis patients. The role of asialoglycoprotein receptors.
    Roccatello D; Picciotto G; Torchio M; Ropolo R; Ferro M; Franceschini R; Quattrocchio G; Cacace G; Coppo R; Sena LM
    Lab Invest; 1993 Dec; 69(6):714-23. PubMed ID: 8264233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis.
    Haberer JP; Schoeffler P; Couderc E; Duvaldestin P
    Br J Anaesth; 1982 Dec; 54(12):1267-70. PubMed ID: 7171414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of cefotaxime on the serum protein binding of sulfisoxazole.
    du Souich P; Calvo R; Erill S
    Biopharm Drug Dispos; 1990 Jul; 11(5):371-9. PubMed ID: 2207291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoxetine disposition and elimination in cirrhosis.
    Schenker S; Bergstrom RF; Wolen RL; Lemberger L
    Clin Pharmacol Ther; 1988 Sep; 44(3):353-9. PubMed ID: 3262026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.